文献速递癫痫

新诊断局灶性癫痫成人患者常用抗癫痫药物的不良事件

The Adverse Effects of Commonly Prescribed Antiseizure Medications in Adults With Newly Diagnosed Focal Epilepsy.
PubMed 文献 · Neurology · 2024-09-13

该前瞻性国际观察性研究纳入225例新诊断局灶性癫痫成人,比较左乙拉西坦、拉莫三嗪、卡马西平和奥卡西平单药治疗的不良事件概况。结果显示各药AEP总分无显著差异,但合并抑郁或焦虑者AEP总分更差;左乙拉西坦较拉莫三嗪报告攻击感的风险高3倍以上,而报告不稳感的可能性约为其一半;左乙拉西坦因不良事件停药比例最高,拉莫三嗪最低。

要点

  • 各抗癫痫药物间不良事件总分无显著差异,合并抑郁或焦虑者不良事件总分更差。
  • 左乙拉西坦较拉莫三嗪报告攻击感的风险高3倍以上,而不稳感风险约为其一半。
  • 左乙拉西坦因不良事件停药比例最高(18%),拉莫三嗪最低(5%)。

核心结论

  • 新诊断局灶性癫痫成人单药治疗中,合并精神疾病者不良事件总体报告更多,与所用抗癫痫药物无关。
  • 左乙拉西坦较拉莫三嗪精神类不良事件风险高3倍以上,不稳感风险约为其一半。
  • 左乙拉西坦因不良事件停药比例最高,拉莫三嗪最低。

研究设计与样本

  • 人类癫痫项目为前瞻性国际观察性研究,纳入治疗开始4个月内、完成AEP和迷你国际神经精神访谈的成人局灶性癫痫患者。
  • 共225例成人纳入,左乙拉西坦132例(59%)、拉莫三嗪55例(24%)、卡马西平19例(8.4%)、奥卡西平19例(8.4%)。
  • 采用多变量广义线性模型和惩罚逻辑回归模型分析AEP总分、单项边际评分及二分类应答。

主要发现

  • 各抗癫痫药物间AEP总分无显著差异。
  • 抑郁患者AEP总分较无抑郁者更差(调整边际评分比1.23,95% CI 1.09-1.39,p=0.001)。
  • 焦虑患者AEP总分较无焦虑者更差(调整边际评分比1.15,95% CI 1.04-1.26,p=0.007)。
  • 调整抑郁和焦虑后,左乙拉西坦使用者报告攻击感的可能性是拉莫三嗪使用者的3倍以上(调整比值比3.38,95% CI 1.07-10.7,p=0.038)。
  • 左乙拉西坦使用者经历不稳感的可能性约为拉莫三嗪使用者的一半(调整比值比0.45,95% CI 0.21-0.99,p=0.047)。

临床怎么用

  • 对成人新诊断局灶性癫痫患者,系统筛查不良事件有助于识别可能妨碍达到有效剂量或完成足疗程试验的问题。
  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Systematic screening can help identify antiseizure medication (ASM)-associated adverse events (AEs) that may preclude patients from reaching effective doses or completing adequate trial periods. The Adverse Event Profile (AEP) is a self-completed instrument to identify the frequency of common AEs associated with ASM use. This study aimed to compare the AE profile of commonly used ASMs in adults with newly diagnosed focal epilepsy. METHODS: The Human Epilepsy Project is a prospective, international, observational study investigating markers of treatment response in newly diagnosed focal epilepsy. Participants were enrolled within 4 months of treatment initiation. Adult participants on levetiracetam, lamotrigine, carbamazepine, or oxcarbazepine monotherapy who completed the AEP and Mini International Neuropsychiatric Interview at enrollment were included. Multivariable generalized linear and penalized logistic regression models assessed differences in total and itemized marginal AEP scores and dichotomized responses ("never/rarely" vs "sometimes/always"). RESULTS: A total of 225 adults initiated on levetiracetam (n = 132, 59%), lamotrigine (n = 55, 24%), carbamazepine (n = 19, 8.4%), or oxcarbazepine (n = 19, 8.4%) were included. There were no significant differences in AEP total scores between ASMs. Patients with depression (adjusted marginal score ratio [aMSR] 1.23, 95% CI 1.09-1.39, p = 0.001) and anxiety (aMSR 1.15, 95% CI 1.04-1.26, p = 0.007) had worse AEP total scores than those without. After adjusting for depression and anxiety, levetiracetam users were >3 times more likely to report feelings of aggression (adjusted odds ratio [aOR] 3.38, 95% CI 1.07-10.7, p = 0.038) and almost half as likely to experience unsteadiness (aOR 0.45, 95% CI 0.21-0.99, p = 0.047) than lamotrigine users. Carbamazepine and oxcarbazepine had the highest rates of discontinuation (42.1%, each), followed by levetiracetam (34.8%) and lamotrigine (16.4%). Levetiracetam users had the highest proportion of discontinuations because of AEs alone (18%), and lamotrigine had the lowest (5%). DISCUSSION: Systematic screening for AEs in adults with newly diagnosed focal epilepsy on ASM monotherapy showed that those with comorbid psychiatric conditions report greater AEs overall, irrespective of ASM. Levetiracetam was associated with >3-fold risk of psychiatric AEs and half the risk of experiencing unsteadiness than lamotrigine. Levetiracetam had the highest proportion of discontinuations because of AEs alone, while lamotrigine had the lowest.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Barnard SN, Chen Z, Kanner AM, et al. The Adverse Effects of Commonly Prescribed Antiseizure Medications in Adults With Newly Diagnosed Focal Epilepsy. Neurology. 2024. PMID: 39270150. doi:10.1212/WNL.0000000000209821

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。